AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma

Lei Guo1, Qilin Huai2, Bolun Zhou2, Jianming Ying1 , Wei Guo2,3 ( )
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, The People's Republic of China
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, The People's Republic of China
Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing, The People's Republic of China
Show Author Information

Abstract

Background

Lung adenocarcinoma (LUAD) is the most common lung cancer worldwide. N6‐methyladenosine (m6A) methylation is a messenger RNA (mRNA) modification that plays a key role in tumor growth, immune microenvironment, and immunotherapy response. This study investigated the expression level, mutation status, prognostic value, and predictive ability for response to anti‐PD‐1 immunotherapy of the m6A methyltransferase KIAA1429 in LUAD.

Methods

This study examined multiple public data cohorts and independent samples from National Cancer Center (NCC) to evaluate the clinical significance and prognostic value of KIAA1429 in LUAD using bioinformatics techniques and immunohistochemical staining. We also evaluated the predictive value of KIAA1429 expression for anti‐PD‐1 immunotherapy efficacy. GSEA analysis was performed using KIAA1429 RNA‐seq data at the tumor tissue level and cellular level to explore the potential molecular mechanism.

Results

In public databases, KIAA1429 was significantly associated with clinicopathological parameters in LUAD patients and had the potential to predict patient prognosis. The mutation characteristics of KIAA1429‐related genes were analyzed and TP53, TTN, CSMD3, and other genes showed high mutation frequencies in LUAD. An independent cohort of 415 samples confirmed that high KIAA1429 expression was significantly associated with poorer prognosis in LUAD patients. Analysis of a small immunotherapy cohort showed that patients with high expression of KIAA1429 had better response after immunotherapy, and the proportion of patients with immunotherapy response was higher in this group.

Conclusions

Our study confirmed that KIAA1429 was highly expressed in LUAD and was significantly associated with poor prognosis. Moreover, KIAA1429 may serve as a potential marker to predict the efficacy of immunotherapy in LUAD.

Graphical Abstract

References

【1】
【1】
 
 
Cancer Innovation
Pages 328-343

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Guo L, Huai Q, Zhou B, et al. Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma. Cancer Innovation, 2022, 1(4): 328-343. https://doi.org/10.1002/cai2.40

1598

Views

84

Downloads

6

Crossref

6

Web of Science

6

Scopus

Received: 25 September 2022
Accepted: 11 November 2022
Published: 16 December 2022
© 2022 The Authors.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.